Protective Role of Cross-Reactive CD8 T Cells Against Dengue Virus Infection

EBioMedicine

Volumn 13, Issue , 2016, Pages 284-293

  Elong Ngono, Annie ^a   Chen, Hui Wen ^b   Tang, William W ^a   Joo, Yunichel ^a   King, Kevin ^a   Weiskopf, Daniela ^a   Sidney, John ^a   Sette, Alessandro ^a   Shresta, Sujan ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cross reactivity; Dengue; T cells; Vaccination

Indexed keywords

CROSS REACTING ANTIBODY; GAMMA INTERFERON; CYTOKINE; EPITOPE; HLA B ANTIGEN;

AMINO ACID SEQUENCE; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENGUE; DENGUE VIRUS; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECONDARY INFECTION; SEROTYPE; VIRAL CLEARANCE; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; CROSS REACTION; DISEASE MODEL; IMMUNOLOGY; METABOLISM; PHENOTYPE; TRANSGENIC MOUSE;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; CYTOKINES; DENGUE; DENGUE VIRUS; DISEASE MODELS, ANIMAL; FEMALE; HLA-B ANTIGENS; IMMUNODOMINANT EPITOPES; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; SEROGROUP;

EID: 84991282421     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2016.10.006     Document Type: Article

References (43)

1. Aguirre, S., Maestre, A.M., Pagni, S., Patel, J.R., Savage, T., Gutman, D., Maringer, K., et al. DENV inhibits type I IFN production in infected cells by cleaving human STING. PLoS Pathog., 8(10), 2012, e1002934, 10.1371/journal.ppat.1002934.
2. Alter, G., Malenfant, J.M., Altfeld, M., CD107a as a functional marker for the identification of natural killer cell activity. J. Immunol. Methods 294:1–2 (2004), 15–22, 10.1016/j.jim.2004.08.008.
3. Ashour, J., Morrison, J., Laurent-Rolle, M., Belicha-Villanueva, A., Plumlee, C.R., Bernal-Rubio, D., Williams, K.L., et al. Mouse STAT2 restricts early dengue virus replication. Cell Host Microbe 8:5 (2010), 410–421, 10.1016/j.chom.2010.10.007.
4. Balsitis, S.J., Williams, K.L., Lachica, R., Flores, D., Kyle, J.L., Mehlhop, E., Johnson, S., Diamond, M.S., Robert Beatty, P., Harris, E., Lethal antibody enhancement of dengue disease in mice is prevented by fc modification. PLoS Pathog., 6(2), 2010, e1000790, 10.1371/journal.ppat.1000790.
5. + T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J. Immunol. (Baltimore, Md.: 1950) 176:5 (2006), 2817–2824.
6. Bhatt, S., Gething, P.W., Brady, O.J., Messina, J.P., Farlow, A.W., Moyes, C.L., Drake, J.M., et al. The global distribution and burden of dengue. Nature 496:7446 (2013), 504–507, 10.1038/nature12060.
7. + T-cell responses in Flavivirus-naive individuals following immunization with a live-attenuated tetravalent dengue vaccine candidate. J. Infect. Dis. 212:10 (2015), 1618–1628, 10.1093/infdis/jiv258.
8. + T lymphocyte expansion, proliferation and activation in dengue fever. PLoS Negl. Trop. Dis., 9(2), 2015, e0003520, 10.1371/journal.pntd.0003520.
9. Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., Limpitikul, W., Tangthawornchaikul, N., Malasit, P., Mongkolsapaya, J., Screaton, G., Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc. Natl. Acad. Sci. U. S. A. 107:39 (2010), 16922–16927, 10.1073/pnas.1010867107.
10. Guy, B., Jackson, N., Dengue vaccine: hypotheses to understand CYD-TDV-induced protection. Nat. Rev. Microbiol. 14:1 (2016), 45–54, 10.1038/nrmicro.2015.2.
11. Guy, B., Briand, O., Lang, J., Saville, M., Jackson, N., Development of the Sanofi Pasteur tetravalent dengue vaccine: one more step forward. Vaccine 33:50 (2015), 7100–7111, 10.1016/j.vaccine.2015.09.108.
12. Guzman, M.G., Halstead, S.B., Artsob, H., Buchy, P., Farrar, J., Gubler, D.J., Hunsperger, E., et al. Dengue: a continuing global threat. Nat. Rev. Microbiol. 8:12 Suppl (2010), S7–16, 10.1038/nrmicro2460.
13. Hadinegoro, S.R., Arredondo-García, J.L., Capeding, M.R., Deseda, C., Chotpitayasunondh, T., Reynaldo, D., Ismail, H.I.H.M., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N. Engl. J. Med. 373:13 (2015), 1195–1206, 10.1056/NEJMoa1506223.
14. Halstead, S.B., Dengue. Lancet (London, England) 370:9599 (2007), 1644–1652, 10.1016/S0140-6736(07)61687-0.
15. Halstead, S.B., Controversies in dengue pathogenesis. Paediatr. Int. Child Health 32:Suppl 1 (2012), 5–9, 10.1179/2046904712Z.00000000045 (May).
16. Halstead, S.B., Russell, P.K., Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine, 2016, 10.1016/j.vaccine.2016.02.004 (February).
17. Jayaratne, S.D., Atukorale, V., Gomes, L., Chang, T., Wijesinghe, T., Fernando, S., Ogg, G.S., Malavige, G.N., Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection. BMC Res. Notes, 5, 2012, 645, 10.1186/1756-0500-5-645.
18. Kuno, G., Chang, G.J., Tsuchiya, K.R., Karabatsos, N., Cropp, C.B., Phylogeny of the genus Flavivirus. J. Virol. 72:1 (1998), 73–83.
19. Low, J.G.H., Ooi, E.-E., Tolfvenstam, T., Leo, Y.-S., Hibberd, M.L., Ng, L.-C., Lai, Y.-L., et al. Early dengue infection and outcome study (EDEN) — study design and preliminary findings. Ann. Acad. Med. Singap. 35:11 (2006), 783–789.
20. Malavige, G.N., Ogg, G., Pathogenesis of severe dengue infection. Ceylon Med. J. 57:3 (2012), 97–100, 10.4038/cmj.v57i3.4701.
21. + T cells to heterologous serotypes. J. Immunol. (Baltimore, Md.: 1950) 175:4 (2005), 2676–2683.
22. Mongkolsapaya, J., Dejnirattisai, W., Xu, X.-n., Vasanawathana, S., Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S., et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:7 (2003), 921–927, 10.1038/nm887.
23. Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., Avirutnan, P., Jairungsri, A., Khemnu, N., et al. T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?. J. Immunol. (Baltimore, Md.: 1950) 176:6 (2006), 3821–3829.
24. Perry, S.T., Prestwood, T.R., Lada, S.M., Benedict, C.A., Shresta, S., Cardif-mediated signaling controls the initial innate response to dengue virus in vivo. J. Virol. 83:16 (2009), 8276–8281, 10.1128/JVI.00365-09.
25. Prestwood, T.R., Morar, M.M., Zellweger, R.M., Miller, R., May, M.M., Yauch, L.E., Lada, S.M., Shresta, S., Gamma interferon (IFN-γ) receptor restricts systemic dengue virus replication and prevents paralysis in IFN-α/β receptor-deficient mice. J. Virol. 86:23 (2012), 12561–12570, 10.1128/JVI.06743-11.
26. Rothman, A.L., Medin, C.L., Friberg, H., Currier, J.R., Immunopathogenesis versus protection in dengue virus infections. Curr. Trop. Med. Rep. 1:1 (2014), 13–20, 10.1007/s40475-013-0009-0.
27. Screaton, G., Mongkolsapaya, J., Yacoub, S., Roberts, C., New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15:12 (2015), 745–759, 10.1038/nri3916.
28. Shresta, S., Sharar, K.L., Prigozhin, D.M., Robert Beatty, P., Harris, E., Murine model for dengue virus-induced lethal disease with increased vascular permeability. J. Virol. 80:20 (2006), 10208–10217, 10.1128/JVI.00062-06.
29. Sidney, J., Southwood, S., Moore, C., Oseroff, C., Pinilla, C., Grey, H.M., Sette, A., Measurement of MHC/peptide interactions by gel filtration or monoclonal antibody capture. Coligan, J.E., et al. (eds.) Current Protocols in Immunology, 2013, 10.1002/0471142735.im1803s100 Chapter 18 (February): Unit 18.3.
30. Simmons, C.P., Dong, T., Chau, N.V., Dung, N.T.P., Chau, T.N.B., Thao, L.T.T., Dung, N.T., Hien, T.T., Rowland-Jones, S., Farrar, J., Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J. Virol. 79:9 (2005), 5665–5675, 10.1128/JVI.79.9.5665-5675.2005.
31. Weiskopf, D., Yauch, L.E., Angelo, M.A., John, D.V., Greenbaum, J.A., Sidney, J., Kolla, R.V., et al. Insights into HLA-restricted T cell responses in a novel mouse model of dengue virus infection point toward new implications for vaccine design. J. Immunol. (Baltimore, Md.: 1950) 187:8 (2011), 4268–4279, 10.4049/jimmunol.1101970.
32. + T cells. Proc. Natl. Acad. Sci. U. S. A. 110:22 (2013), E2046–E2053, 10.1073/pnas.1305227110.
33. Weiskopf, D., Angelo, M.A., Sidney, J., Peters, B., Shresta, S., Sette, A., Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection. J. Virol. 88:19 (2014), 11383–11394, 10.1128/JVI.01108-14.
34. + T cells associated with protective immunity. Proc. Natl. Acad. Sci. U. S. A. 112:31 (2015), E4256–E4263, 10.1073/pnas.1505956112.
35. + T-cell responses against the 4 dengue virus serotypes are associated with distinct patterns of protein targets. J. Infect. Dis. 212:11 (2015), 1743–1751, 10.1093/infdis/jiv289.
36. + T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J. Virol. 89:1 (2015), 120–128, 10.1128/JVI.02129-14.
37. + T cells. J. Immunol. (Baltimore, Md.: 1950) 182:8 (2009), 4865–4873, 10.4049/jimmunol.0801974.
38. + T cell or antibody responses but contribute to protection after vaccination. J. Immunol. (Baltimore, Md.: 1950) 185:9 (2010), 5405–5416, 10.4049/jimmunol.1001709.
39. Yu, C.-Y., Chang, T.-H., Liang, J.-J., Chiang, R.-L., Lee, Y.-L., Liao, C.-L., Lin, Y.-L., Dengue virus targets the adaptor protein MITA to subvert host innate immunity. PLoS Pathog., 8(6), 2012, e1002780, 10.1371/journal.ppat.1002780.
40. Zellweger, R.M., Prestwood, T.R., Shresta, S., Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:2 (2010), 128–139, 10.1016/j.chom.2010.01.004.
41. Zellweger, R.M., Miller, R., Eddy, W.E., White, L.J., Johnston, R.E., Shresta, S., Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. PLoS Pathog., 9(10), 2013, e1003723, 10.1371/journal.ppat.1003723.
42. + T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice. J. Immunol. (Baltimore, Md.: 1950) 193:8 (2014), 4117–4124, 10.4049/jimmunol.1401597.
43. + T cells can mediate short-term protection against heterotypic dengue virus reinfection in mice. J. Virol. 89:12 (2015), 6494–6505, 10.1128/JVI.00036-15.